nausea and vomiting Flashcards

1
Q

other Sxs associated with NV?

A

palor, diaphoresis, tachycardia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

causes of NV

A

GI disorders (flu, pathogen, ulcer, GERD, pancreatitis, cholecystitis, obstruction, tumor, DM gastroparesis), CNS disorders (anxiety, tumor, HA), pain (acute* or chronic), excessive intake of anything (food or alcohol), cyclic vomiting syndrome (bouts of severe NV that can last for days, no known cause, associated with migraine HA, may be triggered by stress, children more often than adults), pregnancy (80%, begins week 4-7, resolves week 20, hyperemesis gravidarum (under 1%))

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

treatment-induced causes of NV

A
anti-neoplastic agents
radiation
opioids
anesthesia
procedures (especially abdominal)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

complications of NV

A

discomfort, dehydration (K+, Na+, Cl-), malnutrition, aspiration pneumonia, anxiety, compromise therapy, decreased QOL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

assessment of NV

A

number of episodes, onset, duration of Sxs, severity (1-10)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

questions to ask patients presenting with NV

A

how long have you had NV?
what color is your vomitus?
how often do you vomit?
is vomiting related to eating? if so, what food and how soon after?
do you have nausea without vomiting?
is the NV associated with … ? (signs of other problems)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

site of action of drugs that treat NV

A
dopamine receptors (D2)
histamine receptors (H1 and H2)
muscarinic receptors - cholinergic receptors (M)
serotonin receptors (5-HT3)
neurokinin receptors (NK-1)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

non-pcol management of NV

A

determine cause
put the gut to rest - clear liquid diet and IV hydration
dietary - avoid favorite foods, avoid fatty, fried, sweet and spicy foods, eat food cold or at room temp
physical - avoid unpleasant sights, sounds and odors that may aggravate, get fresh air, avoid sudden movements, dim lights, acupressure, nerve stimulation therapy (relief band? - returns stomach to a normal rhythm)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

treatment of nausea secondary to dyspepsia

A
antacids (maalox, mylanta, tums, peptobismol)
H2 antagonists (zantac, pepcid)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

antihistamines-anticholinergics to treat NV

A

limited for mod-severe NV
MOA: block histamine and/or muscarinic receptors in the CTZ and NTS centers
SE: drowsiness**, sedation, dry mouth, constipation, blurred vision

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

phenothiazines

A

prochlorperazine, promethazine
MOA: dopamine inhibition at CTZ
SE: dizziness, sedation, dry mouth, hypotension, EPS (children, young adults, elderly)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

serotonin antagonists

A

ondansetron, granisetron, palonosetron
MOA: serotonin inhibition at CTZ, NTS, and GI tract
very effective
SE: mild HA, constipation, dizziness, QT prolongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

advantages/disadvantages of various serotonin antagonists

A

ondansetron: multiple dosage forms (inc. ODT), generic, low cost
granisteron: multiple dosage forms (patch, inj, SC), generic, low cost
palonosetron: long DOA, brand only, no PO dosage form
NO SUPPOSITORY FOR ANY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

granisetron dosage forms

A

sancuso
patch: apply 24-48 hours before chemo, may be worn up to 7 days, avoid sun exposure to site and for up to 10 days, $$$
sustol
ER injection: acute delayed CINV, polymer-based drug delivery technology, efficacy greater than 5 days, 10 mg SC no more often than q 7 days, administer over 20-30 seconds d/t viscosity, not recommended for use longer than 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

butyrophenones

A

MOA: dopamine inhibition at CTZ
SE: sedation, hypotensoin, EPS*
black box warning: risk of EKG abnormalities (need 12-lead EKG + 2-3 hour post-op monitoring)
droperidol
haloperidol (1-5 mg IM/IV/PO q 1-5 hours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

olanzapine

A

MOA: blocks D2, 5-HT2c and 5-HT3 receptors - excellent for breakthrough NV, no IV formula
side effects: sedation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

NK-1 antagonists

A

MOA: neurokinin receptor inhibition at CTZ, NTS and GI tract
SE: fatigue, dizziness, HA
aprepitant: for both acute and delayed CINV, not monotherapy, 125 mg day 1, 80 mg day 2 & 3, drug interactions (must decrease dexamethasone by 50%), expensive
fosaprepiant: for acute CINV, not monotherapy, 150 mg IV day 1, expensive
rolapitant: indicated for delayed CINV, not monotherapy, 180 mg as a single dose 1-2 hours before chemo, SE: neutropenia, hiccups, dec appetite, $$$
netupitant and palonosetron: indicated for both acute and delayed CINV, 300/0.5 mg PO 1-2 hours prior to chemo (covers days 1,2,3), used with dexamethasone, SE: headache, asthenia, dyspepsia, fatigue, constipation, $$$

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

cannabinoid use in NV

A

dronabinol and nabilone
MOA: binds with cannabinoid or CB1 receptors in the brain
efficacy similar to phenothiazines and metoclopramide
indications: unresponsive NV, wasting in patients with chronic disease, stimulate appetite, some pain management, MS
SE: sedation, dry mouth, euphoria, dysphoria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

corticosteroid use in NV

A

MOA: inhibition of cortical input into vomiting center?
SE: insomnia, agitation, mild euphoria
low risk of ADRs
dexamethasone

20
Q

benzo use in NV

A

lorazepam, alprazolam
MOA: inhibition of cortical input into vomiting center
especially useful for anticipating NV - start PO day prior to chemo and IV just prior to chemo
SE: sedation, amnesia

21
Q

benzamide use in NV

A

metoclopramide
MOA: dopamine inhibition at CTZ, serotonin inhibition at CTZ, NTS, & GI tract
dose: 20-50 mg
SE: drowsiness, sedation, diarrhea; restlessness, agitation, EPS (use benadryl to prevent EPS)

22
Q

treating NV associated with severe pain

A

5HT3 antagonists

23
Q

scopolamine

A

apply 6-8 hours before needed

duration = 72 hours

24
Q

dimenhydrinate

A

dramamine

50 mg PO taken 30-60 min before needed

25
meclizine
25 mg PO taken 30-60 min before needed
26
treating NV during pregnancy
``` dietary modifications herbal therapy -ginger root (1 gram in divided doses, efficacy similar to B6, onset is 3 days) -ginger gum -peppermint oil -best for mild cases B6 25 mg TID + doxylamine 12.5 TID metoclopramide 5-10 mg TID ondansetron 4-8 mg up to TID meclizine dimenhydrinate promethazine prochloperazine ```
27
hyperemesis gravidarum treatment
metoclopramide and ondansetron SQ infusions | similar to using an insulin pump
28
post-op NV
very common w older inhaled anesthetic agents patients with multiple risk factors are at highest risk for PONV most common complication associated with ambulatory surgery prevention is more effective than treatment
29
risk factors for PONV
female non-smoker Hx of PONV or motion sickness anesthetic: intra-operative use of volatile anesthetics (less w propofil), use of NO surgical: duration of surgery, type of surgery (laprascopic, craniotomy, ENT)
30
treatment of PONV
low risk: 0-1 factors, no prophylaxis, treat PRN mod-high: 2+ risk factors, prophylaxis with 1-2 antiemetics (1 if using propofol), 5HT3 is DOC, all classes can be used highest risk: always use 2 agents (5HT3 antagonist + metoclopramide or aprepitant) breakthrough: use an agent from a different class if within 6 hours
31
aprepitant in PONV
40 mg 1-3 hours prior to induction of anesthesia
32
acute emesis CINV
begins within 1-2 hours after administration, symptoms reach maximum intensity after 5-6 hours and resolve within 12-24 hours
33
delayed emesis CINV
most difficult to treat follows acute emesis (post 24 hours) - less severe but more bothersome peak onset 48-72 hours after chemotherapy administration gradually diminishes over next 1-3 days may persist up to 1 week after chemotherapy treatment; - may worsen with repeated courses more common with high-doses of certain agents, especially cisplatin no clear MOA, but appears to differ somewhat from acute emesis
34
anticipatory emesis CINV
conditioned response to a conditioned stimuli usually develops after 4-5 cycles of cehmo more common in patients with history of severe uncontrolled emesis generally occurs before treatment begins
35
factors affecting CINV
female age (decreased likelihood as age increases) EtOH intake (less chance in Hx of chronic intake) prior chemo (increases chance if emesis poorly controlled) predisposition to NV (motion sickness) personality (anxious) emetogenic potential of chemo (cisplatin, cyclophospamide + doxorubin) dose and dosage regimen (large doses, later in cycles, less with fractionated regimen) combination therapy
36
preventing acute CINV
assess the individual situation assess the emetogenic potential of the agents and regimen always treat when risk is mod-high use PO therapy whenever possible
37
regimen for prevention of acute CINV in high emetic risk patients
``` 5HT3 antagonist -ondansetron 16 mg PO or 8-16 mg IV -granisetron 2 mg PO or 1 mg IV -palonosetron 0.25 mg IV dexamethasone -12 mg IV/PO day 1, then 8 mg daily days 2-4 aprepitant -125 mg PO day 1 then 80 mg days 2-3 +/- lorazepam 0.5-2 mg IV or PO q46h PRN days 1-4 ``` netupitant: 300 mg PO on day 1 palonosetron: 0.5 mg PO on day 1 dexamethasone: 20 mg PO on day 1, then 8 mg BID on days 2-4 +/- lorazepam: 0.5-2 mg IV or PO q46h PRN days 1-4 olanzapine: 10 mg PO on days 1-4 dexamethasone: 20 mg IV on day 1, then 8 mg BID on days 2-4 palonosetron: 0,25 mg IV on day 1 +/- lorazepam: 0.5-2 mg IV or PO q46h PRN days 1-4
38
prevention of acute CINV in moderate emetic risk patients
``` 5HT3 antagonist (palonosetron is preffered) dexamethasone: days 1-3 ```
39
prevention of acute CINV in low emetic risk patients
``` any of the following: dexamethasone* 12 mg po/IV daily metoclopramide 10-40 mg PO/IV, then q6h prochlorperzine 10 mg PO/IV, then q6h ondansetron 16 mg PO daily granisetron 2 mg PO daily ``` minimal emetic risk: use agents PRN
40
breakthrough NV during chemo
difficult to control give agent from a different* drug class IV or PR administration often required ATC rather than PRN dosing
41
treatment of breakthrough NV during chemo
``` prochloperazine - 10 mg IV q46h PRN nabilone - 1-2 g PO q12h metoclopramide - 10-40 mg IV q46h prn + benadryl 50 mg IV haloperidol - 0.5-2 mg q46h PRN olanzapine - 10 mg PO daily ```
42
delayed NV overview
risk for acute CINV = risk for delayed CINV complete control may only be 50% clinicians often over-estimate efficacy of typical PRN regimens for delayed CINV
43
treatment and prevention of delayed NV
metoclopramide + dexamethasone ondansetron or granisetron + dexamethasone palonosetron +/- dexamethasone olanzapine + 5HT3 aprepitant add something the patient hasn't had carries over from acute treatment.... aprepitant 125 mg 1 hour prior to chemo and then 80 mg on days 2 and 3 plus dexamethsone 4-8 mg x 3-5 days starting on day 2
44
unresponsive delayed NV
nabilone, dronabinol, medical marijuana | better in young patients
45
monitoring antiemetic therapy efficacy
``` volume of vomit frequency and duration of vomiting nausea 0-10 ability to maintain food/liquid # of PRN doses of antiemetics QOL rating ```
46
monitoring antiemetic therapy toxicity
``` sedation/drowsiness dizziness diarrhea headache anticholinergic SE EPS ```